ストックスクリーナーアプリを入手
58.72
3.11%
1.77
アフターアワーズ：
58.66
-0.06
-0.10%
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol-Myers Squibb Co (BMY) Shares Fall 4.0% -- What GF Score of 76 Tells Investors - GuruFocus
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement - TradingKey
Bristol Myers Squibb (BMY) Following FDA Acceptance Has An Undervalued Case - simplywall.st
Bristol-Myers Sues Aurobindo to Block Camzyos Heart Drug Copies - Bloomberg Law News
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio? - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Motley Fool
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled - TradingKey
Bristol Myers Squibb (BMY) FDA Accepts New Drug Application for Mezigdomide - GuruFocus
Bristol Myers Squibb stock holds steady on pipeline focus and oncology portfolio updates - Ad Hoc News
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Benzinga
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays central to the lon - Ad Hoc News
BMY: FDA Accepts New Drug Application for Mezigdomide in Multiple Myeloma Treatment - GuruFocus
FDA accepts Bristol Myers Squibb’s mezigdomide application - Investing.com
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma - Yahoo Finance
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline underpins long-term outl - ad-hoc-news.de
Did FTSE Russell’s Reclassification and Dividend Streak Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Is Bristol-Myers Squibb (BMY) Cheap As Index Changes Reshape Investor Exposure? - Yahoo Finance
BMY Stock Quote Price and Forecast - CNN
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - TradingView
Bristol Myers Squibb Stock And 2 Dividend Defensives For Volatile Markets - simplywall.st
Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky - Yahoo Finance
Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect - Yahoo Finance
Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY? - Yahoo Finance
Bristol Myers Squibb (BMY) Stock Still Looks Undervalued Despite Mixed Risks - simplywall.st
Bristol Myers Squibb (BMY) Stock Looks Cheap On Earnings But Mixed On Value - Yahoo Finance
Bristol-Myers Squibb balances patent headwinds and pipeline bets - AD HOC NEWS
Opdivo from Bristol-Myers Squibban immunotherapy workhorse in lung cancer care - AD HOC NEWS
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ - Fierce Biotech
Bristol Myers Squibb outlines long-term strategy for innovative medicines - AD HOC NEWS
Eaton Vance Focused Value Opportunities Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Classic Value Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb (BMY) Stock Analysis: A Steady Dividend Yield With A Strategic Edge - DirectorsTalk Interviews
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know. - Yahoo Finance
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BMYBristol-Myers Squibb Co Volatility & Greeks - Finviz
Bristol Myers Squibb: Pain First, Payoff Later? - Seeking Alpha
Merck & Bristol Myers Squibb are key partners in trials. Ex... - Moomoo
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Insider Monkey
Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued? - simplywall.st
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Hires Lobbyist on Drug Pricing - Legis1
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Investigations Launched into Bristol Myers Squibb (BMY) and Othe - GuruFocus
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
Beeline ups its Series A round for immune drug work - BioPharma Dive
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates? - Insider Monkey
Bristol Myers Squibb adjusts its growth profile as FTSE Russell reshapes indexes. Dividend and earni - AD HOC NEWS
Exclusive: House China panel questions Bristol Myers, Pfizer and others on trial sites - Endpoints News
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Bristol Myers Squibb updates strategy for Zeposia, shares react to pipeline focus - AD HOC NEWS
Bristol Myers Squibb adjusts expectations on key cancer drug, shares react to analyst debate - AD HOC NEWS
Chemung Canal Trust Co. Increases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Camzyos from Bristol-Myers Squibb Co.targeted heart failure therapy reshapes daily routines - Ad-hoc-news.de
The Opdivo from Bristol-Myers Squibb Co.PD-1 blocker reshapes melanoma therapy - Ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Stock Up 3.9% but GF Value Says Ov - GuruFocus
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
OmniStar Financial Group, Inc.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
2.35%
大文字化:
|
ボリューム (24 時間):